Iktos and Teijin Pharma to Co-Develop New Technology for Small Molecule Drug
DiscoveryParis, France and Tokyo, Japan 5 April 2022 - Iktos, a company specialized in Artificial Intelligence(AI) for new drug design, and Teijin Pharma Limited, the core company of the Teijin Group’s
healthcare business that provides comprehensive healthcare services to improve the quality oflife, today announced a strategic collaboration agreement in Artificial Intelligence for new drug
design.
Under the agreement, Iktos generative modelling technology will be implemented and appliedto several Teijin Pharma’s small molecule drug discovery projects to expedite the identificationof potential pre-clinical candidates. Iktos and Teijin Pharma will collaborate in developing new AI
technology aiming to bring further improvement and speed to the drug design process,leveraging Iktos’ proprietary know-how in AI for Computer Aided Drug Design (CADD) andcomplementing Teijin’s research and development capabilities.
In the recent years, Iktos has emerged as one of the world leaders in AI for drug design,
establishing multiple collaborations with renowned pharmaceutical companies and successfully
developing the AI software platforms Makya™ for new drug design and Spaya™ for synthesis
planning. Iktos’ generative AI technology, based on deep generative models, automaticallydesigns virtual novel molecules presenting the desirable characteristics specified by theresearchers. This approach brings unprecedented efficiency in the exploration of chemical spaceand produces innovative molecule designs with greater freedom to operate. It is a novel solution,
validated through many collaborations, to one of the key challenges in drug design: the rapid
identification of molecules that simultaneously satisfy multiple parameters, such as potency,
selectivity, safety, and project-specific properties.

Based on the recent drastic demographic change and increased health consciousness, Teijin
Pharma is committed to providing healthcare solutions in the priority fields of bone, joint,
rehabilitation, neurology, respiratory, cardiovascular and metabolic diseases. Creating innovativedrugs is one of the company’s core business strategies and Teijin Pharma is now focusing onstrengthening technological foundation for small molecule drugs that play major roles among thedrug modalities for innovative drug discovery.
"We are thrilled and proud to announce a strategic collaboration with Teijin Pharma, a leading
company that contributes to society by providing advanced healthcare solutions.’’ said Yann
Gaston-Mathé, Co-founder and CEO of Iktos. “It is a major recognition for Iktos to be selected byTeijin Pharma as a strategic partner for implementation, development, and application of

INTERNAL

generative modeling technology for new drug design. Iktos has been a pioneer in the applicationof generative models for drug discovery and is recognized as a world leader in the technology
space that has the potential to disrupt the way new therapeutics are designed.’’ “Our ultimate
objective is to expedite drug discovery and achieve time and cost efficiencies for our global
collaborators by using Iktos’s proprietary AI platform and know-how. We are confident thattogether with our Teijin collaborators, we will be able to develop new technology to bring further
speed and efficiency to drug discovery.”“We are delighted to create innovative new small molecule drugs together with Iktos,” said Ichiro
Watanabe, President of Teijin Pharma. “We provide solutions in the field of demographic change
and increased health consciousness and are focusing on the launch of new drugs. Iktos’proprietary AI technology will dramatically accelerate our small molecule drug discovery. We
continue to enhance patients' quality of life by providing new treatment options for diseases withhigh unmet needs.”-----About Iktos
Incorporated in October 2016, Iktos is a start-up company specializing in the development ofartificial intelligence solutions applied to chemical research, more specifically medicinal
chemistry and new drug design. Iktos is developing a proprietary and innovative solution basedon deep learning generative models, which enables, using existing data, the design of moleculesthat are optimized in silico to meet all the success criteria of a small molecule discovery project.
The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D.
Iktos offers its technology both as professional services and as a SaaS software platform, Makya™.
Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI
technology for retrosynthesis.
More information on: http://www.iktos.ai/
Contact information : Yann Gaston-Mathé (CEO) – contact@iktos.com - +33 6 30 07 99 26

About the Teijin GroupTeijin (TSE: 3401) is a technology-driven global group offering advanced solutions in the fields ofenvironmental value; safety, security and disaster mitigation; and demographic change andincreased health consciousness. Originally established as Japan's first rayon manufacturer in1918, Teijin has evolved into a unique enterprise encompassing three core business domains:high-performance materials including aramid, carbon fibers and composites, and also resin andplastic processing, films, polyester fibers and products converting; healthcare including
pharmaceuticals and home healthcare equipment for bone/joint, respiratory andcardiovascular/metabolic diseases, nursing care and pre-symptomatic healthcare; and IT

INTERNAL

including B2B solutions for medical, corporate and public systems as well as packaged softwareand B2C online services for digital entertainment. Deeply committed to its stakeholders, asexpressed in the brand statement “Human Chemistry, Human Solutions,” Teijin aims to be acompany that supports the society of the future. The group comprises more than 170 companies
and employs some 20,000 people across 20 countries worldwide. Teijin posted consolidated salesof JPY 836.5 billion (USD 7.7 billion) and total assets of JPY 1,036.4 billion (USD 9.5 billion) in thefiscal year that ended on March 31, 2021.

Press Contact
Corporate Communications
Teijin Limited
pr@teijin.co.jp